Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 11,255 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Newborn Clear all

Conditions: Facioscapulohumeral Muscular Dystrophy
Interventions: ACE-083, ACE-083 or placebo; Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 15 more

Conditions: Blood and Lymphatic Diseases
Interventions: BIVV003, ST-400; Drug
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2038
U.S. locations: 7
States / cities: Oakland, California • Sacramento, California • Atlanta, Georgia + 3 more

Conditions: Fragile X Syndrome
Interventions: Sertraline, Placebo; Drug
Lead sponsor: Randi J. Hagerman, MD; Other
Eligibility: 24 Months to 68 Months
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Skin Laxity
Interventions: Hybrid Fractional Laser; Device
Lead sponsor: Sciton; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Montclair, New Jersey

Conditions: Severe Combined Immunodeficiency Syndrome
Interventions: CD34+ cells transduced with ADA retrovir; Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 1 Month and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Gout Flare
Interventions: Rilonacept, Indomethacin, Placebo (for Indomethacin), Placebo (for Rilonacept); Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 44
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 40 more

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Month to 11 Months
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 14
States / cities: Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more

Conditions: Hemophilia B
Interventions: AAV5-hFIXco-Padua, Factor IX (FIX); Genetic · Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 19
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more

Conditions: Huntington's Disease
Interventions: VX15/2503, Placebo; Drug
Lead sponsor: Vaccinex Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 24 more

Conditions: Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Interventions: Low-added sugar, high-fat diet, High-added sugar, high-fat CF diet; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Tuberous Sclerosis Complex, Lymphangioleiomyomatosis
Interventions: Not listed
Lead sponsor: David M. Ritter; Other
Eligibility: Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Colorectal Cancer, Hereditary Non-polyposis Colon Cancer
Interventions: counseling intervention, CD-ROM intervention; Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: Newark, Delaware • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Cancer, Sickle Cell Disease
Interventions: Text messaging, Questionnaire, Interviews; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 10 Years to 17 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Primary Hyperoxaluria Type 1, PH1
Interventions: YOLT-203, Placebo; Genetic · Drug
Lead sponsor: YolTech Therapeutics Co., Ltd; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Birmingham, Alabama • Aurora, Colorado • St Louis, Missouri + 1 more

Conditions: Smoking, Acne, Atopic Dermatitis, Aging
Interventions: Skin Surface Lipid Collection and Skin Barrier Function; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 12 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Acute Myeloid Leukemia and Myelodysplastic Syndrome
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Neonatal Abstinence Syndrome
Interventions: Structured psychosocial intervention; Behavioral
Lead sponsor: Dr. Henry Akinbi; Other
Eligibility: Female only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Fanconi Anemia
Interventions: Hematopoietic Stem Cell Transplant, Thymic Shielding During Radiation, Total Body Irradiation, Cyclophosphamide, Fludarabine; Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 1 Day to 18 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lactose Intolerance
Interventions: Milk containing A1 and A2 beta-casein, Milk containing only A2 beta-casein; Other
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Interventions: CTX001; Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 6
States / cities: Palo Alto, California • Chicago, Illinois • New York, New York + 2 more

Conditions: Cystic Fibrosis, Quality of Life
Interventions: Massage Therapy; Procedure
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years to 21 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis, Vaso-occlusive Crisis
Interventions: Rivipansel; Drug
Lead sponsor: GlycoMimetics Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 85
States / cities: Mobile, Alabama • Little Rock, Arkansas • Sacramento, California + 28 more

Conditions: Bronchopulmonary Dysplasia
Interventions: Infasurf, Pulmicort, Sham; Drug · Other
Lead sponsor: East Carolina University; Other
Eligibility: 24 Weeks to 28 Weeks
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 2 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 42
States / cities: Little Rock, Arkansas • Oakland, California • Orange, California + 31 more

Search by objective public record fields.

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

Trial of Sertraline to Treat Children With Fragile X Syndrome

Hybrid Fractional Laser for Treatment of Off Face Body Skin Quality

Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency

Study Utilizing Rilonacept in Gout Exacerbations

Phase 3/Safety & Efficacy of Esomeprazole in Infants

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

FEED-Cystic Fibrosis (FEED-CF)

Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)

Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer

The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease

Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

Sebum Collection and Skin Barrier Function Analysis

Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant

Utility of Psychosocial Intervention in Improving Outcome for Methadone-exposed Infants and Their Mothers

Stem Cell Transplantation for Fanconi Anemia

Comparing the Inflammation, Maldigestion and Symptoms Due to Commercial Milk and A2 Milk

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

The Effects of Massage Therapy on QOL in Youth/Young Adults With Cystic Fibrosis

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.

A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients